Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Fingolimod reduces MS disease activity, compared with glatiramer acetate
Key clinical point: Fingolimod is superior to glatiramer acetate in reducing disease activity in relapsing remitting multiple sclerosis.
Major finding: The 0.5-mg/day dose of fingolimod reduced the annualized relapse rate by approximately 41%, compared with glatiramer acetate.
Study details: A randomized, phase 3 study of 859 patients with relapsing remitting multiple sclerosis.
Disclosures: The study had no sponsorship. Dr. Cree reported receiving consulting fees from AbbVie, Akili, Biogen, EMD Serono, and Novartis.
Citation:
REPORTING FROM CMSC 2019